Skip to content

BioCryst Pharmaceuticals BCRX Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$457.98M-757%$263.86M+397%-$8.78M+92.9%-$35.71M+75.5%-$53.47M+74.4%
$1.52M+19.5%$1.39M+11.5%$1.3M-4.1%$1.28M-12.9%$1.27M-18.3%
$79.73M+9.0%$85.07M+30.0%$82.61M+36.4%$81.26M+46.2%$73.13M+32.3%
$313.1M$347.37M$50.2M
$2.73M+164%$2.47M+120%$2.34M+133%$1.06M-45.3%$1.03M-54.0%
-$309.44M-680%-$13.69M-125%$87.59M+899%$82.51M$53.38M
$62.09M-$349.93M-$135.99M
$66.5M-$14.99M
$310.37M$344.9M$47.86M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does BioCryst Pharmaceuticals generate?
BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
What is BioCryst Pharmaceuticals's free cash flow?
After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
Where does BioCryst Pharmaceuticals's cash flow data come from?
Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.